US General Anesthesia Drugs Market Size- By Route of Administration, By End User- Regional Outlook, Competitive Strategies and Segment Forecast to 2033

Description

Introduction and Overview

According to SPER market research, 'US General Anesthesia Drugs Market Size-By Route of Administration, By End User - Regional Outlook, Competitive Strategies and Segment Forecast to 2033' state that the US General Anesthesia Drugs Market is predicted to reach USD 3.18 Billion by 2033 with a CAGR of 3.6%.

General Anaesthesia in the US A class of medications called drugs is used to cause anaesthesia. Generally speaking, they fall into three categories: sedatives, which help patients rest; neuromuscular blocking drugs, which paralyse muscles; and general anaesthetics, which cause anaesthesia.

Due to the burden on healthcare systems and the cancellation or postponement of elective surgeries, the COVID-19 pandemic is predicted to have a negative effect on the market for general anaesthesia drugs. Increased risks of post-operative complications and mortality were noted in a February 2023 Review for Medical and Pharmacological Sciences article for patients with recent or continuing COVID-19 infections. Anaesthesia use is made more difficult by possible drug interactions and the impossibility of a safe gap between COVID-19 therapy and surgery.

Scope of the Report

Report Metric Details:

Market size available for years: 2019-2033

Base year considered: 2022

Forecast period: 2023-2033

Segments covered: By Route of Administration, By End User

Regions covered: Central Region, North Region, South Region

Companies Covered: Abbott Laboratories, AbbVie, Akorn, AstraZeneca plc, Baxter International Inc., Gilead Sciences, Inc, Heritage Pharmaceuticals Inc., Novartis AG, Par Pharmaceutical, Pfizer Inc., Others

Key Segments Covered:

By End User: Based on the End User, US General Anesthesia Drugs Market is segmented as; Ambulatory Surgery Centres, Hospitals.

By Region: This research also includes data for Central Region, North Region, South Region.

Product Code: PHAR2402

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPER's internal database
- 2.1.4. Premium insight from KOL's
2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges
4.2. COVID-19 Impacts of the US General Anesthesia Drugs Market

5. Market variable and outlook

5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
5.3. PORTER's Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
5.4. Heat Map Analysis

6. Competitive Landscape

6.1. US General Anesthesia Drugs Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in US General Anesthesia Drugs Market

7. US General Anesthesia Drugs Market, By Route of Administration (USD Million)

7.1. US General Anesthesia Drugs Market Value Share and Forecast, By Route of Administration, 2023-2033
7.2. Inhalational
- 7.2.1. Desflurane
- 7.2.2. Isoflurane
- 7.2.3. Nitrous Oxide
- 7.2.4. Sevoflurane
7.3. Intravenous
- 7.3.1. Benzodiazepines
- 7.3.2. Etomidate
- 7.3.3. Fentanyl
- 7.3.4. Ketamine
- 7.3.5. Methohexital Sodium
- 7.3.6. Propofol
- 7.3.7. Remifentanil
- 7.3.8. Others

8. US General Anesthesia Drugs Market, By End User (USD Million)

8.1. US General Anesthesia Drugs Market Value Share and Forecast, By End User, 2023-2033
8.2. Ambulatory Surgery Centres
8.3. Hospitals

9. US General Anesthesia Drugs Market Forecast, 2019-2033 (USD Million)

9.1. US General Anesthesia Drugs Market Size and Market Share

10. US General Anesthesia Drugs Market, By Route of Administration, 2019-2033 (USD Million)

10.1. US General Anesthesia Drugs Market Size and Market Share By Route of Administration (2019-2026)
10.2. US General Anesthesia Drugs Market Size and Market Share By Route of Administration (2027-2033)

11. US General Anesthesia Drugs Market, By End User, 2019-2033 (USD Million)

11.1. US General Anesthesia Drugs Market Size and Market Share By End User (2019-2026)
11.2. US General Anesthesia Drugs Market Size and Market Share By End User (2027-2033)

12. US General Anesthesia Drugs Market, By Region, 2019-2033 (USD Million)

12.1. US General Anesthesia Drugs Market Size and Market Share By Region (2019-2026)
12.2. US General Anesthesia Drugs Market Size and Market Share By Region (2027-2033)
12.3. Central Region
12.4. North Region
12.5. South Region

13. Company Profile

13.1. Abbott Laboratories
- 13.1.1. Company details
- 13.1.2. Financial outlook
- 13.1.3. Product summary
- 13.1.4. Recent developments
13.2. AbbVie
- 13.2.1. Company details
- 13.2.2. Financial outlook
- 13.2.3. Product summary
- 13.2.4. Recent developments
13.3. Akorn
- 13.3.1. Company details
- 13.3.2. Financial outlook
- 13.3.3. Product summary
- 13.3.4. Recent developments
13.4. AstraZeneca plc
- 13.4.1. Company details
- 13.4.2. Financial outlook
- 13.4.3. Product summary
- 13.4.4. Recent developments
13.5. Baxter International Inc.
- 13.5.1. Company details
- 13.5.2. Financial outlook
- 13.5.3. Product summary
- 13.5.4. Recent developments
13.6. Gilead Sciences, Inc
- 13.6.1. Company details
- 13.6.2. Financial outlook
- 13.6.3. Product summary
- 13.6.4. Recent developments
13.7. Heritage Pharmaceuticals Inc.
- 13.7.1. Company details
- 13.7.2. Financial outlook
- 13.7.3. Product summary
- 13.7.4. Recent developments
13.8. Novartis AG
- 13.8.1. Company details
- 13.8.2. Financial outlook
- 13.8.3. Product summary
- 13.8.4. Recent developments
13.9. Par Pharmaceutical
- 13.9.1. Company details
- 13.9.2. Financial outlook
- 13.9.3. Product summary
- 13.9.4. Recent developments
13.10. Pfizer Inc.
- 13.10.1. Company details
- 13.10.2. Financial outlook
- 13.10.3. Product summary
- 13.10.4. Recent developments
13.11. Others